Cost–utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ disease
- 1 December 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 175 (6) , 595-603
Abstract
Objective Little data is in existence about the most cost-effective primary treatment for Graves’ disease. We performed a cost–utility analysis comparing radioactive iodine (RAI), anti-thyroid drugs (ATD) and total thyroidectomy (TT) as first-line therapy for Graves’ disease in England and Australia. Methods We used a Markov model to compare lifetime costs and benefits (quality-adjusted life-years (QALYs)). The model included efficacy, rates of relapse and major complications associated with each treatment, and alternative second-line therapies. Model parameters were obtained from published literature. One-way sensitivity analyses were conducted. Costs were presented in 2015£ or Australian Dollars (AUD). Results RAI was the least expensive therapy in both England (£5425; QALYs 34.73) and Australia (AUD5601; 30.97 QALYs). In base case results, in both countries, ATD was a cost-effective alternative to RAI (£16 866; 35.17 QALYs; incremental cost-effectiveness ratio (ICER) £26 279 per QALY gained England; AUD8924; 31.37 QALYs; ICER AUD9687 per QALY gained Australia), while RAI dominated TT (£7115; QALYs 33.93 England; AUD15 668; 30.25 QALYs Australia). In sensitivity analysis, base case results were stable to changes in most cost, transition probabilities and health-relative quality-of-life (HRQoL) weights; however, in England, the results were sensitive to changes in the HRQoL weights of hypothyroidism and euthyroidism on ATD. Conclusions In this analysis, RAI is the least expensive choice for first-line treatment strategy for Graves’ disease. In England and Australia, ATD is likely to be a cost-effective alternative, while TT is unlikely to be cost-effective. Further research into HRQoL in Graves’ disease could improve the quality of future studies.Keywords
This publication has 19 references indexed in Scilit:
- Comparative Effectiveness of Therapies for Graves' Hyperthyroidism: A Systematic Review and Network Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2013
- Is subtotal thyroidectomy a cost-effective treatment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment optionsSurgery, 2012
- Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical EndocrinologistsThyroid®, 2011
- Treatment Options for Graves Disease: A Cost-Effectiveness AnalysisJournal of the American College of Surgeons, 2009
- Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*Clinical Endocrinology, 2008
- Graves' DiseaseNew England Journal of Medicine, 2008
- The Cost Effectiveness of Treatment Modalities for Thyrotoxicosis in a U.K. CenterThyroid®, 2006
- Graves' Disease with Moderate–Severe Endocrine Ophthalmopathy–Long Term Results of a Prospective, Randomized Study of Total or Subtotal Thyroid ResectionThyroid®, 2005
- Antithyroid Drug-Induced Agranulocytosis: Special Reference to Normal White Blood Cell Count AgranulocytosisThyroid®, 2004
- The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham SurveyClinical Endocrinology, 1995